DNA repair gene ERCC1 and XPD polymorphisms predict glioma susceptibility and prognosis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 6, 2012, Pages 2791-2794

  Chen, Da Qing ^a,b   Yao, Dong Xiao ^a   Zhao, Hong Yang ^a   Yang, Shu Juan ^a,c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Ercc1; Glioma; Polymorphisms; Prognosis; Susceptibility; Xpd

Indexed keywords

EID: 84874102935     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.6.2791     Document Type: Article

References (34)

1. Altaha R, Liang X, Yu JJ, et al. (2004). Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med, 14, 959-70.
2. Batchelor TT, Betensky RA, Esposito JM, et al. (2004). Agedependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res, 10, 228-33.
3. Benhamou S, Sarasin A (2002). ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis, 17, 463-9.
4. Benhamou S, Sarasin A (2005). ERCC2 /XPD gene polymorphisms and lung cancer: a Huge review. Am J Epidemiol, 161, 1-14.
5. Braithwaite E, Wu X, Wang Z (1999). Repair of DNA lesions: mechanisms and relative repair efficiencies. Mutat Res, 424, 207-19.
6. Chen HY, Shao CJ, Shi HL, et al. (2007). Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 visà-vis chemotherapy drug cytotoxicity in human glioma. J Neurooncol, 82, 257-62.
7. Coin F, Bergmann E, Tremeau-Bravard A, et al. (1999). Mutations in XPB and XPD helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH. Embo J, 18, 1357-66.
8. De Laat WL, Jaspers NG, Hoeijmakers JH. (1999). Molecular mechanism of nucleotide excision repair. Genes Dev, 13, 768-85.
9. Flejter WL, McDaniel LD, Johns D, et al. (1992). Correction of xeroderma pigmentosum complementation group D mutant cell phenotypes by chromosome and gene transfer: involvement of the human ERCC2 DNA repair gene. Proc Natl Acad Sci USA, 89, 261-5.
10. Goyal S, Parikh RR, Green C, et al. (2010). Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys, 76, 679-84.
11. Hayes M, Lan C, Yan J, et al. (2011). ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res, 31, 4135-9.
12. Houillier C, Lejeune J, Benouaich-Amiel A, et al. (2006). Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer, 106, 2218-23.
13. Hu XB, Feng Z, Fan YC, et al. (2011). Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to glioma. Asian Pac J Cancer Prev, 12, 2981-4.
14. Jensen NF, Smith DH, Nygård SB, et al. (2012). Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scand J Gastroenterol, 47, 340-55.
15. Kiuru A, Lindholm C, Heinavaara S, et al. (2008). XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neurooncol, 88, 135-142.
16. Kuwabara K, Kumamoto K, Ishibashi K, et al. (2011). The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer. Gan To Kagaku Ryoho, 38, 2224-7.
17. Leichman L, Lawrence D, Leichman CG, et al. (2006). Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival. J Chemother, 18, 514-24.
18. Leng XF, Chen MW, Xian L, et al. (2012). Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res, 31, 25.
19. Liao WY, Shih JY, Chang GC, et al. (2012). Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in nonsmall-cell lung cancer patients treated with gemcitabine/ platinum. J Thorac Oncol, 7, 973-81.
20. Lindahl T, Karran P, Wood RD (1997). DNA excision repair pathways. Curr Opin Genet Dev, 7, 158-69.
21. Liu Y, Scheurer ME, El-Zein R, et al. (2009). Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev, 18, 204-14.
22. Milovic-Kovacevic M, Srdic-Rajic T, Radulovic S, et al (2011). Expression of ERCC1 protein in biopsy specimen predicts survival in advanced ovarian cancer patients treated with platinum-based chemotherapy. J BUON, 16, 708-14.
23. Ohgaki H, Dessen P, Jourde B, et al(2004). Genetic pathways to glioblastoma: A population-based study. Cancer Res, 64, 6892-9.
24. Rajaraman P, Hutchinson A, Wichner S, et al. (2010). DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol, 12, 37-48.
25. Rich JN, Hans C, Jones B, et al (2005). Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res, 65, 4051-508.
26. Sung P, Bailly V, Weber C, et al (1993). Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature, 365, 852-5.
27. Wang LE, Bondy ML, Shen H, et al (2004). Polymorphisms of DNA repair genes and risk of glioma. Cancer Res, 64, 5560-3.
28. Weeda G, Hoeijmakers JH(1993). Genetic analysis of nucleotide excision repair in mammalian cells. Semin Cancer Biol, 4, 105-17.
29. Wrensch M, Kelsey KT, Liu M, et al. (2005). ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro Oncol, 7, 495-507.
30. Yan L, Shu-Ying Y, Shan K, et al. (2012). Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy. Pharmacogenomics, 13, 419-27.
31. Yosunkaya E, Kucukyuruk B, Onaran I, et al. (2010). Glioma risk associateswith polymorphisms of DNA repair genes, XRCC1 and PARP1. Br J Neurosurg, 24, 561-5.
32. Zhang N, Lin LY, Zhu LL, et al. (2012). ERCC1 polymorphisms and risk of adult glioma in a Chinese population: a hospitalbased case-control study. Cancer Invest, 30, 199-202.
33. Zhou K, Liu Y, Zhang H, et al. (2009). XRCC3 haplotypes and risk of gliomas in a Chinese population: a hospital-based case-control study. Int J Cancer, 124, 2948-53.
34. Zhou LQ, Ma Z, Shi XF, et al. (2011). Polymorphisms of DNA repair gene XRCC1 and risk of glioma: a case-control study in Southern China. Asian Pac J Cancer Prev, 12, 2547-50.